Endocrine Balance
Governments Weigh Digital Identity Options for Patient Trust
Governments explore digital identity solutions to enhance patient trust, safety, and privacy in healthcare systems like Waikato.
By Samoyed · Oct 1, 2026
Category: Endocrine Balance
Endocrine Balance
Reviewing Medications at Home for Safety
Reviewing medications at home for safety with a medicines brown bag audit may help reduce errors and harm.
By Samoyed · Sep 30, 2026
Endocrine Balance
Waikato Homes Tackle Dampness, Stale Air with Multi-Pronged Approach
Waikato homes combat dampness and stale air with heat pumps, ventilation systems, and behavioral changes for better indoor air quality.
By emily johnson · Sep 26, 2026
Endocrine Balance
Simple fixes for NZ’s persistent home dampness
Simple fixes for NZ’s persistent home dampness, tackling musty odors and condensation in Waikato and beyond with practical ventilation and insulation s
By Samoyed · Sep 25, 2026
Endocrine Balance
Biotech and Digital Health Firms Expand Boards
Board appointments are reshaping biotech and digital health firms as August brings seasoned executives and scientific leaders onto boards to drive growth.
By Samoyed · Sep 21, 2026
Endocrine Balance
UK drug firms pull out of NICE reviews at record
UK drug firms are pulling out of NICE reviews at record levels in 2026, raising questions about industry shifts or systemic issues in the appraisal...
By Samoyed · Sep 19, 2026
Endocrine Balance
FDA Approves First Gene Therapy for Sanfilippo Syndrome Type A
The FDA has approved the first gene therapy, Fayuvi, for Sanfilippo syndrome type A, offering hope to affected children.
By emily johnson · Sep 18, 2026
Endocrine Balance
Breast cancer drug Etcamah fails first-line trial test
AstraZeneca’s breast cancer drug Etcamah failed its first-line trial, SERENA-4, raising doubts about its potential as a frontline treatment for HR-positive pati
By emily johnson · Sep 15, 2026
Endocrine Balance
Biotechs lead fight against cancer
Biotechs lead the fight against cancer with next-generation treatments and clinical trials.
By emily johnson · Sep 11, 2026
Endocrine Balance
Novartis Announces Positive Phase III Results for Remibrutinib
Novartis announces positive Phase III results for Remibrutinib, a new oral treatment for relapsing multiple sclerosis showing significant efficacy over teriflun
By Samoyed · Sep 1, 2026